SCHEMBL7091816

SCHEMBL7091816

[O]C1(F)CCCC1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7095245 0.92
SCHEMBL23538657 0.90
SCHEMBL7094176 0.79
SCHEMBL7096150 0.74
SCHEMBL1470832 0.71
SCHEMBL28824051 0.70
SCHEMBL7053959 0.69
SCHEMBL7095201 0.68
SCHEMBL35211257 0.67
SCHEMBL7670859 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118344370-A Isoindolinone and indazole compounds for EGFR degradation C4医药公司 2024-07-16 CN disclosed
CN-114901277-B Isoindolinone and indazole compounds for EGFR degradation C4医药公司 2024-05-17 CN disclosed
US-20240158418-A1 EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS C4 THERAPEUTICS, INC. (US) 2024-05-16 US disclosed
EP-4359409-A1 DEGRADER COMPOUNDS AND USES THEREOF Calico Life Sciences LLC (US) 2024-05-01 EP disclosed
EP-4347044-A2 EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS C4 Therapeutics, Inc. (US) 2024-04-10 EP disclosed
US-20240076300-A1 ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR C4 THERAPEUTICS, INC. (US) 2024-03-07 US disclosed
CN-117440813-A EGFR degrading agents for treating brain or CNS cancer metastasis C4医药公司 2024-01-23 CN disclosed
US-11673902-B2 Isoindolinone and indazole compounds for the degradation of EGFR C4 THERAPEUTICS, INC. (US) 2023-06-13 US disclosed
CN-116194453-A Protein tyrosine phosphatase degrading agent and method of use thereof 卡里科生命科学有限责任公司 2023-05-30 CN disclosed
US-20230110648-A1 ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR C4 THERAPEUTICS, INC. (US) 2023-04-13 US disclosed
CN-114901277-A Isoindolinone and indazole compounds for EGFR degradation C4医药公司 2022-08-12 CN disclosed
WO-2021127561-A1 ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR C4 THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
WO-2021127586-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 WO disclosed
US-20030065189-A1 Processes for producing 4-substituted benzopyran derivatives CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-04-03 US disclosed
US-6455708-B1 SUCH AS 2,2-BIS(FLUOROMETHYL)-N-(2-CYANOETHYL)-6-TRIFLUOROMETHYL-2H-1-BENZOPYRAN-4 -CARBOXAMIDE; USEFUL AS MEDICINES, AGRICHEMICALS AND COSMETICS, AND CHEMICAL INTERMEDIATES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-09-24 US disclosed
US-6444616-B1 HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 2002-09-03 US disclosed
EP-1120412-A1 PROCESSES FOR THE PREPARATION OF 4-SUBSTITUTED BENZOPYRAN DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-08-01 EP disclosed
US-6130225-A Substituted p-trifluoromethylphenyluracils BAYER AKTIENGESELLSCHAFT (DE) 2000-10-10 US disclosed
EP-0923562-A1 SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS BAYER AG (DE) 1999-06-23 EP disclosed
WO-1998006706-A1 SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS BAYER AKTIENGESELLSCHAFT (DE) 1998-02-19 WO disclosed